Increased levels of alcohol use are associated with worse HIV care cascade outcomes among adults in Kenya and Uganda Sarah Puryear, MD, MPH University.

Slides:



Advertisements
Similar presentations
MINNESOTAS HIV TREATMENT CASCADE. Introduction This slide set describes the continuum of HIV care in Minnesota. The slides rely on data from HIV/AIDS.
Advertisements

Trends in the Use of Evidence-Based Treatments for Coronary Artery Disease Among Women and the Elderly Findings From the Get With the Guidelines Quality-
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2013.
1 Lauren E. Finn, 2 Seth Sheffler-Collins, MPH, 2 Marcelo Fernandez-Viña, MPH, 2 Claire Newbern, PhD, 1 Dr. Alison Evans, ScD., 1 Drexel University School.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2011.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2010.
Changes in population-level HIV RNA distribution one year after implementation of key components of an HIV ‘test and treat’ strategy in rural Uganda Vivek.
Racial Disparities in Antiretroviral Therapy Use and Viral Suppression among Sexually Active HIV-infected Men who have Sex with Men— United States, Medical.
INCIDENCE AND SURVIVAL TRENDS OF COLORECTAL CANCER FROM 2002 TO 2011 BE Ansa; E Alema-Mensah; MD Claridy; JQ Sheats; B Fontenot, and SA Smith Georgia Regents.
Lipoatrophy and lipohypertrophy are independently associated with hypertension: the effect of lipoatrophy but not lipohypertrophy on hypertension is independent.
Declines in adult HIV mortality in Botswana, : evidence for an impact of antiretroviral therapy programs Rand Stoneburner, Dominic Montagu, Cyril.
MINNESOTA’S HIV TREATMENT CASCADE April, Introduction.
Boston University Slideshow Title Goes Here Eliminating CD4 thresholds in South Africa will not lead to large increases in persons receiving ART without.
UNITAID PSI HIV SELF-TESTING AFRICA
Generalized Logit Model
HPTN 071 (PopART): Have we reached the targets after two years of the PopART intervention IAS Paris July 2017 Richard Hayes.
State Office of AIDS Update
Module 4: Engaging KPs with HIV and SRH Services
Men are absent across the HIV continuum of care in a rural area of southern Mozambique Laura Fuente-Soro, Elisa Lopez-Varela, Orvalho Augusto , Charfudin.
“Early Adopters” of PrEP in SEARCH study in rural Kenya and Uganda
Gaps in the cascade of care in two high prevalence settings in Zimbabwe and Malawi Nolwenn Conan1, Cyrus Paye2, Erica Simons2, Abraham Mapfumo3, Tsitsi.
2Ministry of Health and Child Care, AIDS & TB Unit, Harare, Zimbabwe
Differentiated Service Delivery: Innovating for Impact
Addressing the challenges and successes of expediting TB treatment among PLHIV who are seriously ill: experience from Kenya Masini E & Olwande C National.
HIV treatment cascade analysis for people who inject drugs in Ukraine: identifying the correlates of HIV care outcomes Kostyantyn Dumchev1, Olga Varetska2,
Ana Progovac, PhD1,2,3 Benjamin Lê Cook, PhD MPH 1,2
Conclusions & Implications
BY MAELO DAVID BUMULA SC BUNGOMA COUNTY
Ambassador Deborah L. Birx, MD
Alcohol, Other Drugs, and Health: Current Evidence March–April 2017
Believed discrimination occurred because of their:
A COLLABORATIVE APPROACH TO ESTABLISH PREDICTORS
San Francisco Department of Public Health
TB-HIV Last updated: March 2018.
Double-sided HIV Cascades for Key Populations
WHO HIV update July 2018 Global epidemic Global progress and cascade
International AIDS Economics Network (IAEN) Conference
South African HIV Care Cascades Data Sources
Parastu Kasaie Johns Hopkins University
TB-HIV Last updated: November 2018.
Dr. Velephi Okello, Principal Investigator, MaxART Trial
Dr Celestine Mugambi National AIDS Control Council, Kenya
Baseline characteristics of HPS participants by prior diabetes
Spending More to Spend Less
Correlations #1.
Wafaa El-Sadr, MD, MPH, MPA ICAP at Columbia University
Fatima Oliveira Tsiouris Deputy Director, Clinical & Training Unit
From toward HIV Elimination with Boosted-Integrated Active HIV Case Management (B-IACM) in Cambodia Dr. Penh Sun LY, Director, NCHADS Presented.
Improving Technical Efficiencies:
From trials to programmes: Lessons learned from four trials of Universal Testing and Treatment (UTT) in Sub-Saharan Africa 24th July 2018 Estimates of.
Neel Gandhi, MD VACS Leadership Meeting November 5, 2003
Summary Sheet Figures and Maps
Summary Sheet Figures and Maps
Summary Sheet Figures and Maps
Summary Sheet Figures and Maps
Summary Sheet Figures and Maps
Summary Sheet Figures and Maps
Summary Sheet Figures and Maps
Progress on Voluntary Medical Male Circumcision for HIV prevention and How VMMC fits into UNAIDS ' ' target Julia Samuelson, Nurse epidemiologist.
Summary Sheet Figures and Maps
Summary Sheet Figures and Maps
Summary Sheet Figures and Maps
Summary Sheet Figures and Maps
Cervical Cancer Surveillance, Screening, and Treatment
Response to HIV in Next Decade Definitive way to measure client centered approach to prevention and treatment services Ambassador Deborah Birx, MD PEPFAR.
Andreas D. Haas, PhD Postdoctoral fellow, ICAP at Columbia University
Knowledge of HIV Status in Kenya
HIV Recency Testing in Rwanda
Update on global progress in ART
Prevalence of recent alcohol and substance use in persons with HIV and associations with HIV care cascade outcomes in South Africa Adrienne E Shapiro,
Presentation transcript:

Increased levels of alcohol use are associated with worse HIV care cascade outcomes among adults in Kenya and Uganda Sarah Puryear, MD, MPH University of California, San Francisco sarah.puryear@ucsf.edu No conflicts of interest to declare. Good afternoon everyone. Thank you for this opportunity, thank you to the chairs, and thank you for the introduction. I have no conflicts of interest to declare. My email address is on this screen for any follow up questions you may have. Today I will be presenting on our research in 28 communities in Kenya and Uganda. @UCSF_HIVIDGM

HIV Care Cascade Outcomes by Level of Alcohol Use What we know: Alcohol use leads to poor HIV care outcomes What we do not know: How does alcohol use impact the entire HIV care cascade? Does level of drinking matter? Methods: Compare HIV diagnosis, ART uptake, and viral suppression in HIV+ adult drinkers vs. non-drinkers at SEARCH baseline in rural Kenya and Uganda using TMLE Population HIV testing from April 2013-June 2014: 118,963 HIV tested (90% coverage) 10,268 (8.6%) HIV+  10,067 (98%) alcohol screened  AUDIT-C score determined: 8,441 HIV+ non-drinkers (84%) 1,626 HIV+ drinkers (16%) Drinking Level AUDIT-C Score n (%) Low 1-2 ♀ 1-3 ♂ 774 (48%) Medium 3-5♀ 4-5 ♂ 561 (34%) High 6-7 170 (11%) Very High 8-12 121 (7%) An urgent need exists to understand gaps along the HIV care cascade in order to enable improvement of care and treatment programs for PLHIV. We all know well that alcohol use is a major risk factor for poor HIV care outcomes. And in sub-Saharan Africa, heavy alcohol use is a growing problem. What we do not know, however, is what is the impact of alcohol use on the entire HIV care cascade, from diagnosis to treatment to viral suppression? And does the level of drinking matter? Do only heavy drinkers have poor outcomes? How do low and moderate level drinkers fare?   To answer these questions, we leveraged baseline HIV care cascade data from 28 communities in the SEARCH study, a test-and treat trial, to compare HIV diagnosis, ART uptake, and viral suppression between HIV-positive drinkers and non-drinkers This study was funded by the NIH and PEPFAR. Between April 2013 and June 2014, SEARCH undertook a door-to-door census followed by community-wide HIV testing in rural Uganda and Kenya Individuals were also screened for current alcohol use followed by questions on frequency, intensity and heavy episodic drinking that were mapped to the AUDIT-C scale. We further classified AUDIT-C scores into levels of drinking, as you can see in the table to the right, including non-hazardous low level drinkers (AUDIT 1-2 for women; 1-3 for men), medium (AUDIT 3-5 for women, 4-5 for men), high (6-7) and very high (8-12) Within SEARCH, 90% of the population—a total of 118,963 individuals--had a baseline HIV test 10,268, or 8·6%, tested HIV-positive. Among them, alcohol screening was documented in 98%, or 10,067 individuals, who constituted the study population. Alcohol drinkers accounted for 16% of HIV positive individuals, with 48% reporting low level alcohol use, 34% medium, 11% high, and 7% very high level use. Baseline characteristics were similar between drinkers and non-drinkers, with the exception of sex: 71% of drinkers were male; while only 29% of non-drinkers were male. Characteristics similar, except: Drinkers 71% male Non-Drinkers: 29% Male

Key Finding #1: HIV diagnosis and ART uptake key roadblocks to viral suppression for drinkers Drinkers 12% less likely to be previously diagnosed aRR 0.88 (95% CI: 0.84-0.93) Drinkers 7% less likely to be on ART if previously diagnosed aRR 0.93 (95% CI: 0.89-0.98) No association between any alcohol use and viral suppression if on ART However, high and very-high level drinkers less likely to be virally suppressed if on ART Today I will be presenting just 2 key findings. The first is that, HIV diagnosis and ART uptake were identified as the two key roadblocks to overall viral suppression for drinkers When we looked among HIV positive individuals, we found that HIV+ drinkers—which includes any level of drinking--were 12% less likely to know their HIV-positive status versus non-drinkers. Only 59% of HIV-positive drinkers had been previously diagnosed, compared to 68% of nondrinkers. As you can see in the first set of bar graphs to the left--where the first bar represents non-drinkers, the second all drinkers, and the solid bars the levels of drinking—this was more pronounced at higher levels of alcohol use.   Among those previously HIV diagnosed, drinkers were 7% less likely to be on ART than non-drinkers. In terms of proportions, 77% of drinkers were on ART, compared to 84% of non-drinkers, Among those on ART, there was no association between any alcohol use and viral suppression, however high and very high level use were associated with lower likelihoods of viral suppression (RR: 0.88 [95%CI 0.83-0.94] and 0.87 [95%CI: 0.80-0.96], respectively).

Key Finding #2: Overall viral suppression is worse in drinkers vs. non-drinkers Any alcohol use associated with being 20% less likely to be virally suppressed aRR 0.80 (95%CI 0.76-0.84) Association seen at every level of drinking Trend toward decreasing viral suppression with increased drinking level Our second key finding, and my final slide, is to highlight that any alcohol use was associated with worse overall viral suppression. So when looking at viral suppression regardless of known diagnosis or ART use, drinkers had a lower proportion suppressed at 36% compared to non-drinkers at 45% . And as a reminder this was at baseline—in 2013 to 2014—prior to the universal treatment intervention. Any alcohol use was associated with being 20% less likely to be virally suppressed (RR 0·80, [95%CI 0·76-0·84]). As you can see in the graph—which I would note is scaled to a 50% y-axis-- There was a trend toward decreasing viral suppression with increasing severity of drinking, ranging from low-level use (RR 0·85, [95%CI 0·81-0·90]) to very high-level use (RR 0·64, [95%CI 0·62-0·67]). So in conclusion, we found that alcohol use is associated with gaps in the HIV care cascade at diagnosis and ART uptake, culminating in worse overall viral suppression at trial baseline. Disparities in care cascade outcomes were most pronounced in higher level drinkers, but negative effects were also observed in low and medium level drinkers. Moving forward, we are analyzing the impact of the SEARCH universal testing and treatment intervention to determine if gaps remain for drinkers when barriers to testing and treatment are removed. If you have further questions, I would happy to answer them during the discussion or afterwards   CONCLUSIONS Alcohol use is associated with gaps in the HIV care cascade at diagnosis and ART uptake, culminating in worse overall viral suppression at trial baseline Disparities in care cascade outcomes were most pronounced in higher level drinkers, but negative effects also observed in low- and medium-level drinkers vs. non-drinkers